Science & Technology
Preclinical characterization of splice-modifying antisense oligonucleotides targeting neurogenesis in human AD neural cells
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43AG084445-01A1
Award Ceiling
$505K
Award Floor
$505K
Close Date
Jul 31, 2025
Total Funding
$505K
Expected Awards
1
Posted Date
Aug 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R43AG084445-01A1
Description
SBIR Phase Phase I award: "Preclinical characterization of splice-modifying antisense oligonucleotides targeting neurogenesis in human AD neural cells" awarded to BOLDEN THERAPEUTICS, INC. in PROVIDENCE, Rhode Island. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $504,505. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.